[Interferon alpha 2b eyedrops as treatment of conjunctival intraepithelial neoplasia].
Huerva
V
V
Mangues
I
I
Schoenenberger
J A
JA
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D002278:Carcinoma in Situ / Q000188:drug therapy* / Q000191:economics; D002986:Clinical Trials as Topic; D003230:Conjunctival Neoplasms / Q000188:drug therapy* / Q000191:economics; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D015337:Multicenter Studies as Topic; D009883:Ophthalmic Solutions / Q000191:economics; D011994:Recombinant Proteins; D013030:Spain; D014481:United States
D000970:Antineoplastic Agents; D007155:Immunologic Factors; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D009883:Ophthalmic Solutions; D011994:Recombinant Proteins